Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

USD 36.0

(-7.98%)

Total Liabilities Summary of Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Company Ltd.'s latest annual total liabilities in 2023 was 85.23 Million USD , down -30.71% from previous year.
Biohaven Pharmaceutical Holding Company Ltd.'s latest quarterly total liabilities in 2024 Q1 was 117.08 Million USD , up 37.36% from previous quarter.
Biohaven Pharmaceutical Holding Company Ltd. reported annual total liabilities of 123.01 Million USD in 2022, up 159.68% from previous year.
Biohaven Pharmaceutical Holding Company Ltd. reported annual total liabilities of 47.37 Million USD in 2021, up 36.44% from previous year.
Biohaven Pharmaceutical Holding Company Ltd. reported quarterly total liabilities of 198.9 Million USD for 2024 Q2, up 69.88% from previous quarter.
Biohaven Pharmaceutical Holding Company Ltd. reported quarterly total liabilities of 146.26 Million USD for 2023 Q1, up 18.9% from previous quarter.

Annual Total Liabilities Chart of Biohaven Pharmaceutical Holding Company Ltd. (2023 - 2017)

Historical Annual Total Liabilities of Biohaven Pharmaceutical Holding Company Ltd. (2023 - 2017)

Year	Total Liabilities	Total Liabilities Growth
2023	85.23 Million USD	-30.71%
2022	123.01 Million USD	159.68%
2021	47.37 Million USD	36.44%
2020	34.71 Million USD	-90.13%
2019	351.68 Million USD	152.85%
2018	139.09 Million USD	832.44%
2017	14.91 Million USD	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	117.08 Million USD	37.36%
2024 Q2	198.9 Million USD	69.88%
2023 Q1	146.26 Million USD	18.9%
2023 Q2	119.48 Million USD	-18.31%
2023 Q3	92.73 Million USD	-22.39%
2023 FY	85.23 Million USD	-30.71%
2023 Q4	85.23 Million USD	-8.08%
2022 Q4	123.01 Million USD	247.2%
2022 Q3	35.43 Million USD	-49.8%
2022 Q2	70.58 Million USD	-96.16%
2022 Q1	1.83 Billion USD	3780.37%
2022 FY	123.01 Million USD	159.68%
2021 FY	47.37 Million USD	36.44%
2021 Q1	1.22 Billion USD	19.83%
2021 Q4	47.37 Million USD	-97.15%
2021 Q3	1.66 Billion USD	33.8%
2021 Q2	1.24 Billion USD	1.73%
2020 Q2	459.72 Million USD	11.93%
2020 FY	34.71 Million USD	-90.13%
2020 Q3	935.83 Million USD	103.57%
2020 Q1	410.71 Million USD	16.78%
2020 Q4	1.01 Billion USD	8.9%
2019 Q2	304.16 Million USD	105.42%
2019 FY	351.68 Million USD	152.85%
2019 Q4	351.68 Million USD	9.86%
2019 Q3	320.11 Million USD	5.24%
2019 Q1	148.06 Million USD	6.45%
2018 Q4	139.09 Million USD	7.59%
2018 Q2	120.46 Million USD	557.57%
2018 Q1	18.31 Million USD	0.0%
2018 FY	139.09 Million USD	832.44%
2018 Q3	129.27 Million USD	7.32%
2017 Q1	39.83 Million USD	0.0%
2017 Q3	28.47 Million USD	33.05%
2017 Q2	21.4 Million USD	-46.27%
2017 FY	14.91 Million USD	0.0%
2017 Q4	- USD	-100.0%

Peer Total Liabilities Comparison of Biohaven Pharmaceutical Holding Company Ltd.

Name	Total Liabilities	Total Liabilities Difference
ADC Therapeutics SA	503.03 Million USD	83.055%
Alto Neuroscience, Inc.	158.3 Million USD	46.155%
Annovis Bio, Inc.	17.95 Million USD	-374.617%
Ginkgo Bioworks Holdings, Inc.	568.19 Million USD	84.999%
Nuvation Bio Inc.	16.36 Million USD	-420.945%
Nuvation Bio Inc.	16.36 Million USD	-420.945%
Arcus Biosciences, Inc.	633 Million USD	86.534%
Theriva Biologics, Inc.	20.51 Million USD	-315.506%
Zymeworks Inc.	116.07 Million USD	26.567%